Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Baraclude

- PMLiVE

GSK’s Witty ends on a high, but warns 2017 looking ‘uncertain’

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Change at the top at Teva as Vigodman departs

CEO replaced ad interim by chairman Yitzhak Peterburg as search begins

- PMLiVE

Opdivo gets FDA green light to treat bladder cancer

BMS adds new US indication to its checkpoint inhibitor

- PMLiVE

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

- PMLiVE

Teva Generics Europe appoints president and CEO

Promotes former UK general manager Richard Daniell

- PMLiVE

NICE changes stance on GSK’s asthma drug Nucala

A newly-agreed price cut and additional cost-effectiveness data prompt U-turn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links